Page 2 of 47

Attorney Docket No.: EX04-017C-US

USSN: 10/565,657

Amendments to the Claims

The following listing of the claims will replace all prior versions and listings of claims in the application:

1-30 (canceled)

31. (currently amended) A compound according to formula I,

$$R^2$$
 X^1
 X^2
 X^3

or a pharmaceutically acceptable salt or a stereoisomer, thereof, wherein,

A is a five- to ten-membered ring containing up to three heteroatoms; provided A is not a saturated alicyclic when X^2 is =N-, X^3 is -O-, and A is a pyridin-4-yl;

 R^1 is selected from -H, halo, trihalomethyl, -CN, -NO₂, -OR⁴, -N(R⁴)R⁴, -S(O)₀₋₂R⁴, -SO₂N(R⁴)R⁴, -CO₂R⁴, -C(=O)N(R⁴)R⁴, -C(=O)R⁴, -C(=NR⁵)N(R⁴)R⁴, -C(=NR⁵)R⁴, -N(R⁴)SO₂R⁴, -N(R⁴)C(O)R⁴, alkoxy, C₁₋₆ alkyl, aryl, aryl C₁₋₆ alkyl, heterocyclyl, and heterocyclyl C₁₋₆ alkyl;

two adjacent of R¹, together with the annular atoms to which they are attached, can form a five- to six-membered ring containing up to two heteroatoms and optionally substituted with up to four of R¹⁰;

R² and R³, together with the annular atoms to which they are attached, form a five- to six-membered ring containing up to two heteroatoms and optionally substituted with up to five of R⁶;

each R⁴ is selected from -H; C₁₋₆ alkyl optionally substituted with 1, 2, or 3 halogen; C₁₋₆ alkyl optionally substituted with alkoxy; C₁₋₆ alkyl substituted with amino where the amino is optionally substituted with one or groups selected from methyl, ethyl, -CH₂CH₂OCH₃, -CH₂CH₂N(CH₃)₂, -CH₂CH₂CH₂N(CH₃)₂, and *N*-methyl-pyrrolidin3-yl; aryl; aryl C₁₋₆ alkyl; heterocyclyl; and heterocyclyl C₁₋₆ alkyl where the heterocyclyl is

Attorney Docket No.: EX04-017C-US Page 3 of 47

USSN: 10/565,657

optionally substituted with alkyl, acyl, NH₂, alkylamino, dialkylamino, heterocyclyl, cyclohexyl, -CH₂OCH₃, -CH₂C(O)NHCH(CH₃)₂, or -CH₂OCH₃;

two of R⁴, when taken together with a common nitrogen to which they are attached, form an five- to seven-membered heterocyclyl, said optionally substituted five- to seven-membered heterocyclyl optionally containing at least one additional heteroatom selected from N, O, S, and P;

each R^5 is selected from -H, -CN, -NO₂, -OR⁴, -S(O)₀₋₂R⁴, -CO₂R⁴, C₁₋₆ alkyl, C₂₋₆ alkenyl, and C₂₋₆ alkynyl;

Y is =N- or $=C(H)==C(R^*)$ -;

 X^1 and X^2 are each independently either =N- or =C(\mathbb{R}^9)-;

 X^3 is selected from $-N(R^7)$ -, -O-, and -S-;

R⁷ is hydrogen;

each of R^6 , R^8 —and R^{10} is independently selected from -H, halo, trihalomethyl, -CN, -NO₂, -OR⁴, -N(R⁴)R⁴, -S(O)₀₋₂R⁴, -SO₂N(R⁴)R⁴, -CO₂R⁴, -C(=O)N(R⁴)R⁴, -C(=NR⁵)N(R⁴)R⁴, -C(=NR⁵)R⁴, -N(R⁴)SO₂R⁴, -N(R⁴)C(O)R⁴, -C(=O)R⁴, optionally substituted alkoxy, C_{1-6} alkyl, aryl, aryl C_{1-6} alkyl, heterocyclyl, and heterocyclyl C_{1-6} alkyl;

two adjacent of R⁶, together with the annular atoms to which they are attached, can form a five- to seven-membered ring containing up to two heteroatoms; and

each R^9 is independently selected from -H; halo; trihalomethyl; -CN; -NO₂; -OR⁴; -N(R⁴)R⁴; -S(O)₀₋₂R⁴; -SO₂N(R⁴)R⁴; -CO₂R⁴; -C(=O)N(R⁴)R⁴; -C(=NR⁵)N(R⁴)R⁴; -C(=NR⁵)R⁴; -N(R⁴)SO₂R⁴; -N(R⁴)C(O)R⁴; -C(=O)R⁴; alkoxy; C₁₋₆ alkyl optionally substituted with one group selected from alkoxy, benzylamino, and 2-oxo-pyrrolidinyl; aryl C₁₋₆ alkyl substituted on the aryl with 1 or 2 groups selected from alkyl and alkoxy; heterocyclyl optionally substituted with -C(O)Ot-Bu; and heterocyclyl C₁₋₆ alkyl; provided when R^9 is aryl, heteroaryl, -C(H)=C(H)R or -C(H)=NR, where R is an optionally substituted alkyl, cycloalkyl, heteroalicyclic, aryl, or heteroaryl, then Y is not =C(H)-

Attorney Docket No.: EX04-017C-US

USSN: 10/565.657

Page 4 of 47

- 32. (previously presented) The compound according to claim 31, wherein the five- to six-membered ring formed by R² and R³ is an aryl or a heteroaryl optionally substituted with up to five of R⁶; or a pharmaceutically acceptable salt or stereoisomer, thereof.
- 33. (previously presented) The compound according to claim 32, wherein the five- to six-membered ring formed by R^2 and R^3 is phenyl or pyridyl optionally substituted with up to five of R^6 ; or a pharmaceutically acceptable salt or stereoisomer, thereof.
- 34. (previously presented) The compound according to claim 33, of formula II,

$$1-4(R^6)$$
 X^1
 X^2
 X^3

or a pharmaceutically acceptable salt or stereoisomer, thereof.

- 35. (previously presented) The compound according to claim 34, wherein X^1 is $=C(R^9)$ -, X^2 is =N-, X^3 is $-N(R^7)$ -, and R^7 is hydrogen; or a pharmaceutically acceptable salt or stereoisomer, thereof.
- 36. (previously presented) The compound according to claim 35, wherein Y is =N-; or a pharmaceutically acceptable salt or stereoisomer, thereof.
- 37. (currently amended) The compound according to claim 36, wherein A is either a six- to ten-membered aryl or a five- to ten-membered heteroaryl containing up to three heteroatoms and where A is substituted with 1-5 R¹; or a pharmaceutically acceptable salt or stereoisomer, thereof.
- 38. (currently amended) The compound according to claim 37, wherein A is either a six-membered aryl or a five- or six-membered heteroaryl containing up to three heteroatoms and where A is substituted with 1-5 R¹; or a pharmaceutically acceptable salt or stereoisomer, thereof.
- 39. (previously presented) The compound according to claim 38, wherein R^1 is selected from -H, halo, trihalomethyl, -CN, -OR⁴, -N(R⁴)R⁴, -SO₂N(R⁴)R⁴, -CO₂R⁴, -C(=O)N(R⁴)R⁴, -C(=NR⁵)N(R⁴)R⁴, -C(=NR⁵)R⁴, -N(R⁴)SO₂R⁴, -N(R⁴)C(O)R⁴, alkoxy,

Attorney Docket No.: EX04-017C-US

USSN: 10/565,657

Page 5 of 47

 C_{1-6} alkyl, heterocyclyl, and heterocyclyl C_{1-6} alkyl; or a pharmaceutically acceptable salt or stereoisomer, thereof.

40. (previously presented) The compound according to claim 39, of formula III,

wherein R⁷ is hydrogen and at least one of R¹ is -OH; or a pharmaceutically acceptable salt or stereoisomer, thereof.

41. (previously presented) The compound according to claim 40, wherein the compound is either of Formula IIa or IIIb:

$$(R^{6})_{1-4}^{II}$$
 $(R^{6})_{1-4}^{II}$
 $(R^{6})_{1-4}^{II}$
 $(R^{1})_{1-4}$
 $(R^{1})_{1-4}$
 $(R^{1})_{1-4}$
 $(R^{1})_{1-4}$
 $(R^{1})_{1-4}$

or a pharmaceutically acceptable salt or stereoisomer, thereof.

- 42. (previously presented) The compound according to claim 41, wherein R^9 is selected from –H; trihalomethyl; C_{1-6} alkyl optionally substituted with one group selected from alkoxy, benzylamino, and 2-oxo-pyrrolidinyl; aryl C_{1-6} alkyl substituted on the aryl with 1 or 2 groups selected from alkyl and alkoxy; heterocyclyl optionally substituted with -C(O)Ot-Bu; and heterocyclyl C_{1-6} alkyl; or a pharmaceutically acceptable salt or stereoisomer, thereof.
- 43. (previously presented) The compound according to claim 42, wherein R^6 is selected from -H, halo, trihalomethyl, -CN, -OR⁴, -N(R⁴)R⁴, -CO₂R⁴, -C(=O)N(R⁴)R⁴, -N(R⁴)SO₂R⁴, -N(R⁴)C(O)R⁴, -C(=O)R⁴, C₁₋₆ alkyl, heterocyclyl, heterocyclyl C₁₋₆ alkyl, and a six- or seven-membered heteroalicyclic formed by two adjacent of R^6 , together

USSN: 10/565,657

with the annular atoms to which they are attached, said six- or seven-membered heteroalicyclic containing up to two heteroatoms; or a pharmaceutically acceptable salt or stereoisomer, thereof.

- 44. (previously presented) The compound according to claim 43, wherein R^6 is selected from -H, halo, $-OR^4$, $-N(R^4)R^4$, C_{1-6} alkyl, heterocyclyl, heterocyclyl C_{1-6} alkyl, and a six-or seven-membered heteroalicyclic formed by two adjacent of R^6 , together with the annular atoms to which they are attached, said six- or seven-membered heteroalicyclic containing up to two heteroatoms; or a pharmaceutically acceptable salt or stereoisomer, thereof.
- 45. (previously presented) The compound according to claim 44, wherein at least one of R⁶ is -OR⁴ and R⁴ is C₁₋₆ alkyl optionally substituted with 1, 2, or 3 halogen; C₁₋₆ alkyl optionally substituted with alkoxy; C₁₋₆ alkyl substituted with amino where the amino is optionally substituted with one or groups selected from methyl, ethyl, -CH₂CH₂OCH₃, -CH₂CH₂N(CH₃)₂, -CH₂CH₂N(CH₃)₂, and *N*-methyl-pyrrolidin3-yl; and heterocyclyl where the heterocyclyl is optionally substituted with alkyl, acyl, NH₂, alkylamino, dialkylamino, heterocyclyl, cyclohexyl, -CH₂OCH₃, -CH₂C(O)NHCH(CH₃)₂, or -CH₂OCH₃; or a pharmaceutically acceptable salt or stereoisomer, thereof.
- 46. (previously presented) The compound according to claim 45, wherein at least one of R¹ is halo or methyl; or a pharmaceutically acceptable salt or stereoisomer, thereof.
- 47 (previously presented) The compound according to claim 46, wherein R^9 is selected from -H, trihalomethyl, and C_{1-6} alkyl optionally substituted with one group selected from alkoxy, benzylamino, and 2-oxo-pyrrolidinyl; or a pharmaceutically acceptable salt or stereoisomer, thereof.
- 48. (previously presented) The compound according to claim 44, wherein at least one of R⁶ is -OR⁴ and R⁴ is heterocyclyl C₁₋₆ alkyl where the heterocyclyl is a heteroalicyclic; or a pharmaceutically acceptable salt or stereoisomer, thereof.
- 49 (previously presented) The compound according to claim 48, wherein said heteroalicyclic is selected from the group consisting of dioxolanyl, piperidinyl, piperazinyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, 2-oxoazepinyl,

Page 7 of 47

Attorney Docket No.: EX04-017C-US

USSN: 10/565,657

azepinyl, 4-piperidonyl, pyrrolidinyl, morpholinyl, quinuclidinyl, tetrahydrofuryl, tetrahydropyranyl, thiamorpholinyl, thiamorpholinyl sulfoxide, 2,5-diazabicyclo[2.2.1]heptanyl, and thiamorpholinyl sulfone; or a pharmaceutically acceptable salt or stereoisomer, thereof.

50. (currently amended) The compound according to claim 44, A compound according to Formula IIIa or IIIb

$$(R^{6})_{1-4} \stackrel{\text{III}}{\overset{\text{III}}}{\overset{\text{III}}{\overset{\text{III}}{\overset{\text{III}}{\overset{\text{III}}{\overset{\text{III}}{\overset{\text{III}}{\overset{\text{III}}{\overset{\text{III}}{\overset{\text{III}}{\overset{\text{III}}{\overset{\text{III}}{\overset{\text{III}}{\overset{\text{III}}}{\overset{\text{III}$$

wherein

each R^1 is independently selected from -H, halo, trihalomethyl, -CN, -OR⁴, -N(R⁴)R⁴, -SO₂N(R⁴)R⁴, -C(=O)N(R⁴)R⁴, -C(=NR⁵)N(R⁴)R⁴, -C(=NR⁵)R⁴, -N(R⁴)SO₂R⁴, -N(R⁴)C(O)R⁴, C₁₋₆ alkyl, heterocyclyl, and heterocyclyl C₁₋₆ alkyl,

R⁹ is selected from -H; trihalomethyl; C₁₋₆ alkyl optionally substituted with one group selected from alkoxy, benzylamino, and 2-oxo-pyrrolidinyl; aryl C₁₋₆ alkyl substituted on the aryl with 1 or 2 groups selected from alkyl and alkoxy; heterocyclyl optionally substituted with -C(O)Ot-Bu; and heterocyclyl C₁₋₆ alkyl; and

wherein at least one of R⁶ is -OR⁴ and R⁴ is alkyl substituted with at least one additional of alkoxyl, amino, dialkylamino, and monoalkylamino where the <u>amino of the</u> monoalkylamino is further sbustitued with N-methyl-pyrrolidin3-yl and where each alkyl of monoalkylamino and dialkylamino are independently optionally substituted with -NH₂, -NHCH₃, or -N(CH-)₂; or a pharmaceutically acceptable salt or stereoisomer, thereof.

USSN: 10/565,657

51. (previously presented) The compound according to claim 31, selected from Table 3; or a pharmaceutically acceptable salt or stereoisomer, thereof

Table 3

	13016.5		
Entry	Name	Structure	
10	4-{7,8-bis(methyloxy)-1-[(4-methylphenyl)methyl]-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl}phenol	HO NEW THE NEW	
12	4-(7,8-bis(methyloxy)-1-{[4- (methyloxy)phenyl]methyl}- 3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin- 5-yl)phenol	HO NO	
13	4-{7,8-bis(methyloxy)-1-[(2-methylphenyl)methyl]-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl}phenol	HO N N N N N N N N N N N N N N N N N N N	
14	4-{7,8-bis(methyloxy)-1-[(3-methylphenyl)methyl]-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl}phenol	HO N N N N N N N N N N N N N N N N N N N	
15	4-[1-methyl-7,8-bis(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	HO N N N N N N N N N N N N N N N N N N N	

Table 3

Entry	Name	Structure
20	4-[1-{[3,4-bis(methyloxy)phenyl]methyl}-7,8-bis(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	HO N N N N N N N N N N N N N N N N N N N
21	4-(7,8-bis(methyloxy)-1-{[3-(methyloxy)phenyl]methyl}-3H-pyrazolo[3,4-c]isoquinolin-5-yl)phenol	HO N N N N N N N N N N N N N N N N N N N
22	4-[1-ethyl-7,8-bis(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	HO N N N N N N N N N N N N N N N N N N N
25	4-[1-methyl-6,7,8- tris(methyloxy)-3 <i>H</i> - pyrazolo[3,4- <i>c</i>]isoquinolin-5- yl]phenol	HO N N N N N N N N N N N N N N N N N N N
27	4-[7,8-bis(methyloxy)-1- (trifluoromethyl)-3 <i>H</i> - pyrazolo[3,4- <i>c</i>]isoquinolin-5- yl]phenol	HO N F F

Table 3

Entry	Name	Structure
28	4-[1-(1-methylethyl)-7,8-bis(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	HO N N N N N N N N N N N N N N N N N N N
29	4-[7,8-bis(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	HO NH NH
31	4-[1-methyl-6,8-bis(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	HO N N N N N N N N N N N N N N N N N N N
32	4-[6,8-bis(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	HO N N N
34	4-[6,7,8-tris(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	HO N N N N N N N N N N N N N N N N N N N

Table 3

Entry	Name	Structure
35	4-[1-methyl-7,8,9- tris(methyloxy)-3 <i>H</i> - pyrazolo[3,4- <i>c</i>]isoquinolin-5- yl]phenol	HO N N N N N N N N N N N N N N N N N N N
36	4-[1-methyl-8-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	HO N N N N N N N N N N N N N N N N N N N
37	2-methyl-4-[1-methyl-7,8-bis(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	HZ P
38	4-[1-methyl-7,8-bis(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]-2-(methyloxy)phenol	HO N N N N N N N N N N N N N N N N N N N
39	4-{1-methyl-8-(methyloxy)-7- [(2-morpholin-4-ylethyl)oxy]- 3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin- 5-yl}phenol	

Table 3

Entry	Name	Structure
40	2-(ethyloxy)-4-[1-methyl-7,8-bis(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	HO N N N N N N N N N N N N N N N N N N N
41	2-chloro-4-[1-methyl-7,8-bis(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	HO N N H
42	2-fluoro-4-[1-methyl-7,8-bis(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	HO N N N N N N N N N N N N N N N N N N N
44	2-bromo-4-[1-methyl-7,8-bis(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	Br N N N
45	1-{[5-(4-hydroxyphenyl)-7,8-bis(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-1-yl]methyl}pyrrolidin-2-one	HO N N N

Table 3

Entry	Name	Structure
54	4-{ 1-methyl-7-(methyloxy)-8- [(piperidin-4-ylmethyl)oxy]- 3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin- 5-yl}phenol	HN NH
55	4-{1-methyl-8-(methyloxy)-7- [(piperidin-4-ylmethyl)oxy]- 3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin- 5-yl}phenol	OH NH
58	4-[8-(ethyloxy)-1-methyl-7- (methyloxy)-3 <i>H</i> -pyrazolo[3,4- c]isoquinolin-5-yl]phenol	HO NO
59	4-[1-methyl-8,9-bis(methyloxy)-3 <i>H</i> -pyrazolo[3,4-c]isoquinolin-5-yl]phenol	HO N N N N N N N N N N N N N N N N N N N
60	4-[7-(ethyloxy)-1-methyl-8- (methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	HO N N N N N N N N N N N N N N N N N N N

Table 3

Entry	Name	Structure
61	4-{1-methyl-8-(methyloxy)-9- [(piperidin-4-ylmethyl)oxy]- 3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin- 5-yl}phenol	HO NH NH
63	2-ethyl-4-[1-methyl-7,8-bis(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	HO N N N N N N N N N N N N N N N N N N N
64	4-(1-methyl-8-(methyloxy)-9- {[(1-methylpiperidin-4- yl)methyl]oxy}-3 <i>H</i> - pyrazolo[3,4- <i>c</i>]isoquinolin-5- yl)phenol	HO C C C C C C C C C C C C C C C C C C C
65	4-(1-methyl-7-(methyloxy)-8- {[(1-methylpiperidin-4- yl)methyl]oxy}-3 <i>H</i> - pyrazolo[3,4- <i>c</i>]isoquinolin-5- yl)phenol	N. NH
66	4-[1,7-dimethyl-8-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	HO N N N N N N N N N N N N N N N N N N N

Table 3

Entry	Name .	Structure
67	1,1-dimethylethyl 4-[5-(4-hydroxyphenyl)-7,8-bis(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-1-yl]piperidine-1-carboxylate	H Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z
69	2-chloro-4-[1-methyl-8,9-bis(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	HO N N N N N N N N N N N N N N N N N N N
70	2-fluoro-4-[1-methyl-8,9-bis(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	HO N N N N N N N N N N N N N N N N N N N
71	2-methyl-4-[1-methyl-8,9-bis(methyloxy)-3 <i>H</i> -pyrazolo[3,4-c]isoquinolin-5-yl]phenol	HO NH NH
72	2-bromo-4-[1-methyl-8,9-bis(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	HO N N N N N N N N N N N N N N N N N N N
76	2-[(difluoromethyl)oxy]-4-[1-methyl-7,8-bis(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	F HO N H

Table 3

Entry	Name	Structure
78	4-[1,9-dimethyl-8-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	HO N N N N N N N N N N N N N N N N N N N
79	4-[6,9-difluoro-1-methyl-8- (methyloxy)-3 <i>H</i> -pyrazolo[3,4- c]isoquinolin-5-yl]phenol	HO N N N N N N N N N N N N N N N N N N N
80	2-bromo-4-{1-methyl-8- (methyloxy)-9-[(2-morpholin- 4-ylethyl)oxy]-3 <i>H</i> - pyrazolo[3,4- <i>c</i>]isoquinolin-5- yl}phenol	H Z O O O O O O O O O O O O O O O O O O
81	2-chloro-4-{1-methyl-8- (methyloxy)-9-[(2-morpholin- 4-ylethyl)oxy]-3 <i>H</i> - pyrazolo[3,4-c]isoquinolin-5- yl}phenol	N N O O O O O O O O O O O O O O O O O O
82	4-(7,8-bis(methyloxy)-1- {[(phenylmethyl)amino]methyl} }-3H-pyrazolo[3,4- c]isoquinolin-5-yl)phenol	HO N N N N N N N N N N N N N N N N N N N

Table 3

Entry	Name	Structure
83	2,5-dimethyl-4-[1-methyl-7,8-bis(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	HO N N N N N N N N N N N N N N N N N N N
85	2,5-dichloro-4-[1-methyl-7,8-bis(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	CI N N N H
87	2-bromo-4-(1-methyl-8- (methyloxy)-9-{[(1- methylpiperidin-4- yl)methyl]oxy}-3 <i>H</i> - pyrazolo[3,4- <i>c</i>]isoquinolin-5- yl)phenol	HO Br
88	2-chloro-4-(1-methyl-7- (methyloxy)-8-{[(1- methylpiperidin-4- yl)methyl]oxy}-3 <i>H</i> - pyrazolo[3,4- <i>c</i>]isoquinolin-5- yl)phenol	N-NH N-NH N-OH CI
89	4-[9-fluoro-1-methyl-8- (methyloxy)-3 <i>H</i> -pyrazolo[3,4- c]isoquinolin-5-yl]phenol	HO N N N N N N N N N N N N N N N N N N N

Table 3

Entry	Name	Structure
90	4-(1-methyl-8-(methyloxy)-9- {[2-(methyloxy)ethyl]oxy}-3 <i>H</i> - pyrazolo[3,4- <i>c</i>]isoquinolin-5- yl)phenol	NH NO OH
91	2-chloro-4-(1-methyl-8- (methyloxy)-9-{[(1- methylpiperidin-4- yl)methyl]oxy}-3 <i>H</i> - pyrazolo[3,4- <i>c</i>]isoquinolin-5- yl)phenol	-O - C - Z - Z - Z - Z - Z - Z - Z - Z - Z
92	4-[6-bromo-1,7-dimethyl-8- (methyloxy)-3 <i>H</i> -pyrazolo[3,4- c]isoquinolin-5-yl]phenol	HO N N N H
93	4-[6-fluoro-1-methyl-7,8-bis(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	HO N N N N H
94	4-[9-chloro-1,7-dimethyl-8- (methyloxy)-3 <i>H</i> -pyrazolo[3,4- c]isoquinolin-5-yl]phenol	HO CI

Table 3

Entry	Name	Structure
95	2-chloro-4-[8-{[(1- ethylpiperidin-4- yl)methyl]oxy}-1-methyl-7- (methyloxy)-3 <i>H</i> -pyrazolo[3,4- c]isoquinolin-5-yl]phenol	N-NH OH CI
96	3-chloro-4-[1-methyl-7,8-bis(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	HZ COV
97	4-(1-methyl-8,9-bis{[2- (methyloxy)ethyl]oxy}-3H- pyrazolo[3,4-c]isoquinolin-5- yl)phenol	HO N N N N N N N N N N N N N N N N N N N
98	4-(1-methyl-3 <i>H</i> -pyrazolo[3,4- c]isoquinolin-5-yl)phenol	HO N N N N N N N N N N N N N N N N N N N
99	2-chloro-4-(1-methyl-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)phenol	HO N N N N N N N N N N N N N N N N N N N
100	2-bromo-4-(1-methyl-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)phenol	HO N N N N N N N N N N N N N N N N N N N

Table 3

Entry	Name	Structure
101	2-chloro-4-[1,7-dimethyl-8- (methyloxy)-3 <i>H</i> -pyrazolo[3,4- c]isoquinolin-5-yl]phenol	HO N N N N N N N N N N N N N N N N N N N
102	2-bromo-4-[1,7-dimethyl-8- (methyloxy)-3 <i>H</i> -pyrazolo[3,4- c]isoquinolin-5-yl]phenol	HO N N N N N N N N N N N N N N N N N N N
103	2-chloro-4-[1-methyl-8-({[1-(1-methylethyl)piperidin-4-yl]methyl}oxy)-7-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	H Z O O O
104	4-[9-bromo-1-methyl-8- (methyloxy)-3 <i>H</i> -pyrazolo[3,4- c]isoquinolin-5-yl]phenol	HO N N N N N N N N N N N N N N N N N N N
105	4-[7-chloro-9-fluoro-1-methyl- 8-(methyloxy)-3 <i>H</i> - pyrazolo[3,4-c]isoquinolin-5- yl]phenol	HO P N N H

Table 3

Entry	Name	Structure
106	4-[8-{[(1-acetylpiperidin-4-yl)methyl]oxy}-1-methyl-7-(methyloxy)-3 <i>H</i> -pyrazolo[3,4-c]isoquinolin-5-yl]-2-chlorophenol	H Z O
107	4-[9-{[(1-acetylpiperidin-4-yl)methyl]oxy}-1-methyl-8-(methyloxy)-3 <i>H</i> -pyrazolo[3,4-c]isoquinolin-5-yl]-2-bromophenol	
108	2-chloro-4-(1-methyl-9- (methyloxy)-8-{[2- (methyloxy)ethyl]oxy}-3H- pyrazolo[3,4-c]isoquinolin-5- yl)phenol	H Z Z Z
109	. 4-[7-fluoro-1-methyl-8- (methyloxy)-3 <i>H</i> -pyrazolo[3,4- c]isoquinolin-5-yl]phenol	HO N N N N N N N N N N N N N N N N N N N
110	2-chloro-4-(1-methyl-8,9-bis{[2-(methyloxy)ethyl]oxy}-3H-pyrazolo[3,4-c]isoquinolin-5-yl)phenol	

Table 3

Entry	Name	Structure
111	2-bromo-4-(1-methyl-8,9-bis{[2-(methyloxy)ethyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)phenol	Br O O O O O O O O O O O O O O O O O O O
112	2-chloro-4-(1-methyl-8- (methyloxy)-9-{[2- (methyloxy)ethyl]oxy}-3H- pyrazolo[3,4-c]isoquinolin-5- yl)phenol	N N O H O H
113	2-bromo-4-(1-methyl-8- (methyloxy)-9-{[2- (methyloxy)ethyl]oxy}-3H- pyrazolo[3,4-c]isoquinolin-5- yl)phenol	N N N OH OH
114	3-fluoro-4-[1-methyl-7,8-bis(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	HO N N N
115	2-chloro-4-(1-methyl-7- (methyloxy)-8-{[2- (methyloxy)ethyl]oxy}-3 <i>H</i> - pyrazolo[3,4- <i>c</i>]isoquinolin-5- yl)phenol	HO N N N N N N N N N N N N N N N N N N N

Table 3

Entry	Name	Structure
116	2-bromo-4-(1-methyl-7- (methyloxy)-8-{[2- (methyloxy)ethyl]oxy}-3 <i>H</i> - pyrazolo[3,4- <i>c</i>]isoquinolin-5- yl)phenol	Br NH
117	2-chloro-4-(1-methyl-7,8-bis{[2-(methyloxy)ethyl]oxy}-3H-pyrazolo[3,4-c]isoquinolin-5-yl)phenol	HO N N N N N N N N N N N N N N N N N N N
118	2-bromo-4-(1-methyl-7,8-bis{[2-(methyloxy)ethyl]oxy}-3H-pyrazolo[3,4-c]isoquinolin-5-yl)phenol	Br N N N N N N N N N N N N N N N N N N N
120	4-(6,9-difluoro-1-methyl-8-{[2-(methyloxy)ethyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)phenol	H C F S S S S S S S S S S S S S S S S S S
121	2-chloro-5-fluoro-4-[1-methyl-7,8-bis(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	

Table 3

Entry	Name	Structure
122	2-bromo-5-fluoro-4-[1-methyl-7,8-bis(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	Br N N N N N N N N N N N N N N N N N N N
123	4-[9-fluoro-1-methyl-7,8-bis(methyloxy)-3 <i>H</i> -benzo[e]indazol-5-yl]phenol	D H Z Z I
125	3-fluoro-4-(1-methyl-7- (methyloxy)-8-{[2- (methyloxy)ethyl]oxy}-3H- pyrazolo[3,4-c]isoquinolin-5- yl)phenol	H Z Z Z
126	4-(6,9-difluoro-1-methyl-8-{[2-(methyloxy)ethyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)-3-fluorophenol	OH F N N N N N N N N N N N N N N N N N N
127	2-chloro-4-(6,9-difluoro-1- methyl-8-{[2- (methyloxy)ethyl]oxy}-3 <i>H</i> - pyrazolo[3,4-c]isoquinolin-5- yl)phenol	CI F O N N N N N N N N N N N N N N N N N N

Table 3

Entry	Name	Structure
128	2-chloro-4-[8-(ethyloxy)-1-methyl-7-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	CI N N H
129	2-chloro-4-[6-chloro-1-methyl-7,8-bis(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	H N OH
130	3-fluoro-4-(1-methyl-9- (methyloxy)-8-{[2- (methyloxy)ethyl]oxy}-3 <i>H</i> - pyrazolo[3,4- <i>c</i>]isoquinolin-5- yl)phenol	H N N N N N N N N N N N N N N N N N N N
131	2-chloro-4-(1,7-dimethyl-8-{[2-(methyloxy)ethyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)phenol	CI N N N N N N N N N N N N N N N N N N N
132	3-fluoro-4-(6-fluoro-1-methyl-7-(methyloxy)-8-{[2-(methyloxy)ethyl]oxy}-3H-pyrazolo[3,4-c]isoquinolin-5-yl)phenol	H Z H

Table 3

Entry	Name	Structure
133	2-chloro-4-[1-methyl-8-[(1-methylethyl)oxy]-7-(methyloxy)-3 <i>H</i> -pyrazolo[3,4-c]isoquinolin-5-yl]phenol	HO N N N H
134	2-chloro-4-{1-methyl-7- (methyloxy)-8-[(2- methylpropyl)oxy]-3 <i>H</i> - pyrazolo[3,4- <i>c</i>]isoquinolin-5- yl}phenol	H Z OH
135	2-bromo-5-fluoro-4-(1-methyl-7-(methyloxy)-8-{[2-(methyloxy)ethyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)phenol	H N OH Br
136	4-[7,8-bis(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]-2-chlorophenol	H N OH
137	4-[7,8-bis(methyloxy)-1- (trifluoromethyl)-3 <i>H</i> - pyrazolo[3,4-c]isoquinolin-5- yl]-2-chlorophenol	CI FFF F F F F F F F F F F F F F F F F F

Table 3

Entry	Name	Structure
138	4-{7,8-bis(methyloxy)-1- [(methyloxy)methyl]-3 <i>H</i> - pyrazolo[3,4-c]isoquinolin-5- yl}-2-chlorophenol	HO N N N N N N N N N N N N N N N N N N N
139	2-chloro-4-(1-methyl-3 <i>H</i> - [1,3]dioxolo[4,5- g]pyrazolo[3,4- <i>c</i>]isoquinolin-5- yl)phenol	HO N N N N N N N N N N N N N N N N N N N
140	2-chloro-4-(1-methyl-8,9-dihydro-3 <i>H</i> -[1,4]dioxino[2,3-g]pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)phenol	CI N N N N N N N N N N N N N N N N N N N
141	2-chloro-4-(1-methyl-9,10-dihydro-3 <i>H</i> ,8 <i>H</i> -[1,4]dioxepino[2,3-g]pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)phenol	HO NH
142	2-chloro-4-[7- [(difluoromethyl)oxy]-1- methyl-8-(methyloxy)-3 <i>H</i> - pyrazolo[3,4-c]isoquinolin-5- yl]phenol	F F O T N H

Table 3

Entry	Name	Structure
143	2-chloro-5-fluoro-4-(6-fluoro- 1-methyl-9-(methyloxy)-8-{[2- (methyloxy)ethyl]oxy}-3 <i>H</i> - pyrazolo[3,4- <i>c</i>]isoquinolin-5- yl)phenol	H N F OH
144	2-chloro-4-(6,9-difluoro-1- methyl-8-{[2- (methyloxy)ethyl]oxy}-3H- pyrazolo[3,4-c]isoquinolin-5- yl)-5-fluorophenol	CI F F N N N N N N N N N N N N N N N N N
145	2-chloro-4-(11-methyl-2,3-dihydro-9 <i>H</i> -[1,4]dioxino[2,3-f]pyrazolo[3,4- <i>c</i>]isoquinolin-7-yl)phenol	HO N N N N N N N N N N N N N N N N N N N
146	2-chloro-5-fluoro-4-(11-methyl-2,3-dihydro-9 <i>H</i> -[1,4]dioxino[2,3-f]pyrazolo[3,4- <i>c</i>]isoquinolin-7-yl)phenol	NH NH OH CI
147	2-chloro-4-[1-methyl-6,7,8- tris(methyloxy)-3 <i>H</i> - pyrazolo[3,4- <i>c</i>]isoquinolin-5- yl]phenol	

Table 3

Entry	Name	Structure
148	2-bromo-4-(6,9-difluoro-1-methyl-8-{[2-(methyloxy)ethyl]oxy}-3H-pyrazolo[3,4-c]isoquinolin-5-yl)-5-fluorophenol	Br F P P P P P P P P P P P P P P P P P P
149	7-(3-chlorophenyl)-11-methyl- 2,3-dihydro-9 <i>H</i> - [1,4]dioxino[2,3- f]pyrazolo[3,4- <i>c</i>]isoquinoline	H Z C C
150	2-chloro-5-fluoro-4-(6-fluoro- 1-methyl-8,9-dihydro-3 <i>H</i> - [1,4]dioxino[2,3- g]pyrazolo[3,4- <i>c</i>]isoquinolin-5- yl)phenol	CI F N N N N N N N N N N N N N N N N N N
151	2-chloro-4-{1-methyl-7- (methyloxy)-8- [(tetrahydrofuran-2- ylmethyl)oxy]-3 <i>H</i> - pyrazolo[3,4-c]isoquinolin-5- yl}phenol	NH NO HOLD
152	2-chloro-4-{1-methyl-7- (methyloxy)-8-[(tetrahydro-2 <i>H</i> - pyran-2-ylmethyl)oxy]-3 <i>H</i> - pyrazolo[3,4- <i>c</i>]isoquinolin-5- yl}phenol	DH Z OH
153	2-chloro-4-{1-methyl-7- (methyloxy)-8-[(2,2,2- trifluoroethyl)oxy]-3 <i>H</i> - pyrazolo[3,4- <i>c</i>]isoquinolin-5- yl}phenol	P F F OH

Table 3

Entry	Name	Structure
154	2-chloro-5-fluoro-4-[9-fluoro- 1-methyl-6,7,8-tris(methyloxy)- 3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin- 5-yl]phenol	
155	5-(3-chloro-4-hydroxyphenyl)-6,9-difluoro-1-methyl-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-8-ol	F CI HO F OH
156	6,9-difluoro-5-(2-fluorophenyl)-1-methyl-8-{[2-(methyloxy)ethyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinoline	P NH
157	2-chloro-4-{8- [(difluoromethyl)oxy]-6,9- difluoro-1-methyl-3 <i>H</i> - pyrazolo[3,4- <i>c</i>]isoquinolin-5- yl}phenol	E - C
158	2-chloro-4-(6,11-difluoro-1- methyl-8,9-dihydro-3 <i>H</i> - [1,4]dioxino[2,3- g]pyrazolo[3,4- <i>c</i>]isoquinolin-5- yl)-5-fluorophenol	CI F N H
159	4-(1-methyl-3 <i>H</i> -benzo[e]indazol-5-yl)phenol	он .

Table 3

Entry	Name '	Structure
160	6-fluoro-7-(2-fluorophenyl)-11- methyl-2,3-dihydro-9 <i>H</i> - [1,4]dioxino[2,3- f]pyrazolo[3,4- <i>c</i>]isoquinoline	NH F
161	2-chloro-4-{1-methyl-7- (methyloxy)-8-[(tetrahydro-2 <i>H</i> - pyran-4-ylmethyl)oxy]-3 <i>H</i> - pyrazolo[3,4- <i>c</i>]isoquinolin-5- yl}phenol	H Z OH
162	2-chloro-4-[8-{[2- (ethyloxy)ethyl]oxy}-1-methyl- 7-(methyloxy)-3 <i>H</i> - pyrazolo[3,4- <i>c</i>]isoquinolin-5- yl]phenol	CI N N N N N N N N N N N N N N N N N N N
164	3-fluoro-4-(6-fluoro-11-methyl- 2,3-dihydro-9 <i>H</i> - [1,4]dioxino[2,3- f]pyrazolo[3,4- <i>c</i>]isoquinolin-7- yl)phenol	N-NH N-NH N-NH N-NH N-NH
165	2-chloro-5-fluoro-4-(6-fluoro- 11-methyl-2,3-dihydro-9 <i>H</i> - [1,4]dioxino[2,3- f]pyrazolo[3,4- <i>c</i>]isoquinolin-7- yl)phenol	N-NH N F OH CI
166	2-chloro-4-[8-(cyclopentyloxy)-1-methyl-7-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	N-NH N-OH CI

Table 3

Entry	Name	Structure
167	2-chloro-4-(1-methyl-7-(1-methylethyl)-8-{[2-(methyloxy)ethyl]oxy}-3H-pyrazolo[3,4-c]isoquinolin-5-yl)phenol	HO N N N N N N N N N N N N N N N N N N N
168	2-chloro-4-[9-ethyl-1-methyl-8- (methyloxy)-3 <i>H</i> -pyrazolo[3,4- c]isoquinolin-5-yl]phenol	HO N N N N N N N N N N N N N N N N N N N
169	2-chloro-4-(6,9-difluoro-1-methyl-8-{[(1-methylpiperidin-4-yl)methyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)phenol	H Z G G G G G G G G G G G G G G G G G G
170	5-(3-chloro-4-hydroxyphenyl)- 8-fluoro-1-methyl-7- (methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-6-ol	HO N N N N N N N N N N N N N N N N N N N
171	2-chloro-4-(6-fluoro-1-methyl-7-(methyloxy)-8-{[(1-methylpiperidin-4-yl)methyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)phenol	N O O O O

Table 3

Entry	Name	Structure
172	2-chloro-4-(6-fluoro-1-methyl- 8,9-bis{[2- (methyloxy)ethyl]oxy}-3 <i>H</i> - pyrazolo[3,4- <i>c</i>]isoquinolin-5- yl)phenol	CI F O O O O O O O O O O O O O O O O O O
173	5-[3-chloro-4- (methyloxy)phenyl]-6-fluoro-1- methyl-7-(methyloxy)-8-{[(1- methylpiperidin-4- yl)methyl]oxy}-3H- pyrazolo[3,4-c]isoquinoline	-N NH N -O F CI
174	5-[3-chloro-4- (methyloxy)phenyl]-8-fluoro-1- methyl-7-(methyloxy)-3 <i>H</i> - pyrazolo[3,4- <i>c</i>]isoquinolin-6-ol	HO N N N N N N N N N N N N N N N N N N N
176	2-chloro-4-{6-fluoro-1-methyl-7-(methyloxy)-8-[(2-piperidin-1-ylethyl)oxy]-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl}phenol	NH NH CI
177	2-chloro-4-[8-{[2-(4- ethylpiperazin-1-yl)ethyl]oxy}- 6-fluoro-1-methyl-7- (methyloxy)-3 <i>H</i> -pyrazolo[3,4- c]isoquinolin-5-yl]phenol	

Table 3

Entry	Name	Structure
178	2-chloro-4-[8-{[2- (diethylamino)ethyl]oxy}-6- fluoro-1-methyl-7-(methyloxy)- 3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin- 5-yl]phenol	N-NH N-NH OFFOH
179	2-chloro-4-(6-fluoro-1-methyl-7-(methyloxy)-8-{[2-(methyloxy)ethyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)phenol	CI F O N N N N N N N N N N N N N N N N N N
182	2-chloro-4-(6-fluoro-1-methyl- 9-(methyloxy)-8-{[(1- methylpiperidin-4- yl)methyl]oxy}-3 <i>H</i> - pyrazolo[3,4- <i>c</i>]isoquinolin-5- yl)phenol	N-NH N-NH N-NH N-OH CI
183	2-bromo-4-(6-fluoro-1-methyl- 9-(methyloxy)-8-{[(1- methylpiperidin-4- yl)methyl]oxy}-3H- pyrazolo[3,4-c]isoquinolin-5- yl)phenol	N O H Br
184	2-chloro-5-fluoro-4-(6-fluoro- 1-methyl-9-(methyloxy)-8-{[(1- methylpiperidin-4- yl)methyl]oxy}-3H- pyrazolo[3,4-c]isoquinolin-5- yl)phenol	NH NH OH OH

Table 3

Entry	Name	Structure
185	4-(6-fluoro-1-methyl-9- (methyloxy)-8-{[(1- methylpiperidin-4- yl)methyl]oxy}-3 <i>H</i> - pyrazolo[3,4- <i>c</i>]isoquinolin-5- yl)-2-methylphenol	N-NH N O F OH
186	2-chloro-4-{6,9-difluoro-1- methyl-8-[(2-piperidin-1- ylethyl)oxy]-3 <i>H</i> -pyrazolo[3,4- c]isoquinolin-5-yl}phenol	N-NH F OH CI
187	2-chloro-4-(8-{[2-(4-ethylpiperazin-1-yl)ethyl]oxy}-6,9-difluoro-1-methyl-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)phenol	H Z O D O O O O O O O O O O O O O O O O O
188	2-chloro-4-(8-{[2- (diethylamino)ethyl]oxy}-6,9- difluoro-1-methyl-3 <i>H</i> - pyrazolo[3,4- <i>c</i>]isoquinolin-5- yl)phenol	N-NH OH OH
191	6,9-difluoro-5-(1 <i>H</i> -indol-5-yl)- 1-methyl-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-8-ol	HN N N N N N N N N N N N N N N N N N N
193	5-(4-aminophenyl)-6,9- difluoro-1-methyl-3 <i>H</i> - pyrazolo[3,4- <i>c</i>]isoquinolin-8-ol	H_2N N N N N N N N N N

Table 3

	_	adie 3
Entry	Name	Structure
194	2-chloro-4-(6-fluoro-1-methyl-7-(methyloxy)-8-{[2-(4-methylpiperazin-1-yl)ethyl]oxy}-3 <i>H</i> -pyrazolo[3,4-c]isoquinolin-5-yl)phenol	N F CI
195	5-(2-amino-1,3-thiazol-5-yl)-6,9-difluoro-1-methyl-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-8-ol	F NH ₂
196	2-chloro-4-[8-{[2-(4-ethylpiperazin-1-yl)ethyl]oxy}-6-fluoro-1-methyl-9-(methyloxy)-3 <i>H</i> -pyrazolo[3,4-c]isoquinolin-5-yl]phenol	
197	2-chloro-4-(6-fluoro-1-methyl-9-(methyloxy)-8-{[2-(4-methylpiperazin-1-yl)ethyl]oxy}-3 <i>H</i> -pyrazolo[3,4-c]isoquinolin-5-yl)phenol	H Z G G G G G G G G G G G G G G G G G G
198	5-(6-aminopyridin-3-yl)-6,9- difluoro-1-methyl-3 <i>H</i> - pyrazolo[3,4- <i>c</i>]isoquinolin-8-ol	H_2N N N N N N N N N N
199	5-(5-amino-2-thienyl)-6,9- difluoro-1-methyl-3 <i>H</i> - pyrazolo[3,4- <i>c</i>]isoquinolin-8-ol	OH F Z Z I

Table 3

Entry	Name	Structure
200	2-chloro-4-[8-{[3-(4-ethylpiperazin-1-yl)propyl]oxy}-6-fluoro-1-methyl-9-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	N, NH N NH CI OH
201	2-chloro-4-(6-fluoro-1-methyl-9-(methyloxy)-8-{[3-(4-methylpiperazin-1-yl)propyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)phenol	N, NH OH OH OH
202	6,9-difluoro-5-(1 <i>H</i> -indol-6-yl)- 1-methyl-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-8-ol	HO HZ
203	N-[5-(6,9-difluoro-8-hydroxy- 1-methyl-3 <i>H</i> -pyrazolo[3,4- c]isoquinolin-5-yl)-1,3-thiazol- 2-yl]acetamide	OH F ZH
206	2-chloro-4-{6-fluoro-1-methyl-9-(methyloxy)-8-[(2-morpholin-4-ylethyl)oxy]-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl}phenol	H Z O O
207	4-[8-({2- [butyl(ethyl)amino]ethyl}oxy)- 6-fluoro-1-methyl-9- (methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]-2- chlorophenol	N-NH N-NH N-NH N-OH CI

Table 3

Entry	Name	Structure
208	4-[8-{[(2R)-2-amino-3-methylbutyl]oxy}-6-fluoro-1-methyl-9-(methyloxy)-3H-pyrazolo[3,4-c]isoquinolin-5-yl]-2-chlorophenol	H ₂ N OH
209	2-chloro-4-(6-fluoro-1-methyl- 9-(methyloxy)-8-{[2-(1- methylpiperidin-4- yl)ethyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)phenol	NH NO H
210	2-chloro-4-[8-{[(1- ethylpiperidin-4- yl)methyl]oxy}-6-fluoro-1- methyl-9-(methyloxy)-3 <i>H</i> - pyrazolo[3,4- <i>c</i>]isoquinolin-5- yl]phenol	N O O O O O O O O O O O O O O O O O O O
212	5-(5-amino-1,3,4-thiadiazol-2-yl)-6,9-difluoro-1-methyl-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-8-ol	F HO
213	4-[8-{[(2R)-2-amino-3,3-dimethylbutyl]oxy}-6-fluoro-1-methyl-9-(methyloxy)-3H-pyrazolo[3,4-c]isoquinolin-5-yl]-2-chlorophenol	CI F-O NH2

Table 3

Entry	Name	Structure
214	2-chloro-4-[6-fluoro-1-methyl-9-(methyloxy)-8-({2-[4-(2-methylpropyl)piperazin-1-yl]ethyl}oxy)-3 <i>H</i> -pyrazolo[3,4-c]isoquinolin-5-yl]phenol	OH CI F N
215	2-chloro-4-[8-{[2-(5-ethyl-2,5-diazabicyclo[2.2.1]hept-2-yl)ethyl]oxy}-6-fluoro-1-methyl-9-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	N-NH N-NH N-NH OH CI
216	2-chloro-4-[6-fluoro-1-methyl- 8-({2-[4-(1- methylethyl)piperazin-1- yl]ethyl}oxy)-9-(methyloxy)- 3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin- 5-yl]phenol	
217	4-[8-{[2-(3-amino-8-azabicyclo[3.2.1]oct-8-yl)ethyl]oxy}-6-fluoro-1-methyl-9-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]-2-chlorophenol	H ₂ N O H
218	2-chloro-4-[8-{[2-(1-ethylpiperidin-4-yl)ethyl]oxy}-6-fluoro-1-methyl-9-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	OH CI

Table 3

Entry	Name	Structure
219	2-chloro-4-[8-{[2- (diethylamino)ethyl]oxy}-6- fluoro-1-methyl-9-(methyloxy)- 3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin- 5-yl]phenol	N-NH N O F O CI
220	2-chloro-5-{6-fluoro-1-methyl-9-(methyloxy)-8-[(2-pyrrolidin-1-ylethyl)oxy]-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl}phenol	N, NH N N OH CI
223	2-chloro-4-[6-fluoro-1-methyl-8-[(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)oxy]-9-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	OH CI NO
224	2-chloro-4-{6-fluoro-1-methyl-9-(methyloxy)-8-[(3-pyrrolidin-1-ylpropyl)oxy]-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl}phenol	N-NH N-NH N-NH N-NH N-NH N-NH N-NH N-NH
225	2-chloro-4-{6-fluoro-1-methyl-9-(methyloxy)-8-[(3-piperidin-1-ylpropyl)oxy]-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl}phenol	N-NH N O F CI

Table 3

Entry	Name	Structure
226	2-chloro-4-{6-fluoro-1-methyl-9-(methyloxy)-8-[(3-morpholin-4-ylpropyl)oxy]-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl}phenol	N-NH N-NH N-NH N-NH N-OH CI
227	2-chloro-4-[8-({2-[[2-(dimethylamino)ethyl](methyl) amino]ethyl}oxy)-6-fluoro-1-methyl-9-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	N-NH N-NH N-NH N-NH N-OH CI
228	2-chloro-4-[8-({2-[[2- (diethylamino)ethyl](methyl)a mino]ethyl}oxy)-6-fluoro-1- methyl-9-(methyloxy)-3 <i>H</i> - pyrazolo[3,4- <i>c</i>]isoquinolin-5- yl]phenol	OH CI P N N N N N N N N N N N N N N N N N N
229	2-chloro-4-[8-({2-[[2-(dimethylamino)ethyl](ethyl)a mino]ethyl}oxy)-6-fluoro-1-methyl-9-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	OH CC FF O
230	4-[8-[(2-{bis[3- (dimethylamino)propyl]amino} ethyl)oxy]-6-fluoro-1-methyl-9- (methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]-2- chlorophenol	OH CI F N N N N N N N N N N N N N N N N N N

Table 3

Entry	Name	Structure
231	2-chloro-4-[6-fluoro-1-methyl-8-({2-[methyl(1-methylpyrrolidin-3-yl)amino]ethyl}oxy)-9-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	H NH NH NH CI
232	2-chloro-4-{6-fluoro-1-methyl-9-(methyloxy)-8-[(2-{(2\$)-2-[(methyloxy)methyl]pyrrolidin-1-yl}ethyl)oxy]-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl}phenol	HO F F F F F F F F F F F F F F F F F F F
233	2-chloro-4-(6-fluoro-1-methyl-9-(methyloxy)-8-{[2-(4-pyrrolidin-1-ylpiperidin-1-yl)ethyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)phenol	H Z O H O O O
234	2-chloro-4-[8-{[2-(4-cyclohexylpiperazin-1-yl)ethyl]oxy}-6-fluoro-1-methyl-9-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	NH N OH OH
235	2-[4-(2-{[5-(3-chloro-4-hydroxyphenyl)-6-fluoro-1-methyl-9-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-8-yl]oxy}ethyl)piperazin-1-yl]- <i>N</i> -(1-methylethyl)acetamide	

Table 3

Entry	Name	Structure
236	4-[8-{[2-(1,4'-bipiperidin-1'-yl)ethyl]oxy}-6-fluoro-1-methyl-9-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]-2-chlorophenol	HO CI N N N N N N N N N N N N N N N N N N
237	2-chloro-4-[6-fluoro-1-methyl- 8-{[2-(4-methyl-1,4-diazepan- 1-yl)ethyl]oxy}-9-(methyloxy)- 3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin- 5-yl]phenol	HO N N N N N N N N N N N N N N N N N N N
238	2-chloro-4-(6-fluoro-1-methyl- 9-(methyloxy)-8-{[2-(4- pyridin-2-ylpiperazin-1- yl)ethyl]oxy}-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl)phenol	NH N OH OH
239	2-chloro-4-[8-{[2-(2,6-dimethylmorpholin-4-yl)ethyl]oxy}-6-fluoro-1-methyl-9-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	OH CI N N N N N N N N N N N N N N N N N N N
240	2-chloro-4-{6-fluoro-1-methyl-9-(methyloxy)-8-[(2-thiomorpholin-4-ylethyl)oxy]-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl}phenol	S N O F CI

Table 3

Entry	Name	Structure
241	2-chloro-4-[8-{[2-(2,6-dimethylpiperidin-1-yl)ethyl]oxy}-6-fluoro-1-methyl-9-(methyloxy)-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl]phenol	N-NH N-NH N-OH CI
242	2-chloro-4-(6-fluoro-1-methyl- 9-(methyloxy)-8-{[2- (octahydroquinolin-1(2H)- yl)ethyl]oxy}-3H-pyrazolo[3,4- c]isoquinolin-5-yl)phenol	N O H CI
243	4-[8-({2-[bis(1-methylethyl)amino]ethyl}oxy)-6-fluoro-1-methyl-9-(methyloxy)-3 <i>H</i> -pyrazolo[3,4-c]isoquinolin-5-yl]-2-chlorophenol	N-NH N O F O O H CI
244	4-[8-[(2-{bis[2- (methyloxy)ethyl]amino}ethyl) oxy]-6-fluoro-1-methyl-9- (methyloxy)-3H-pyrazolo[3,4- c]isoquinolin-5-yl]-2- chlorophenol	OH CI N N N N N N N N N N N N N N N N N N
245	2-chloro-4-{6-fluoro-1-methyl-9-(methyloxy)-8-[(2-piperidin-1-ylethyl)oxy]-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-5-yl}phenol	H NH NH CI

USSN: 10/565,657

52. (previously presented) A Compound selected from

9	4-[7,8-bis(methyloxy)-1- (phenylmethyl)-3 <i>H</i> - pyrazolo[3,4-c]isoquinolin-5- yl]benzene-1,2-diol	HO N N N N
19	4-[7,8-bis(methyloxy)-1-(1-phenylethyl)-3 <i>H</i> -pyrazolo[3,4-c]isoquinolin-5-yl]phenol	HO N N N N N N N N N N N N N N N N N N N
24	4-[6,7,8-tris(methyloxy)-1- (phenylmethyl)-3 <i>H</i> - pyrazolo[3,4- <i>c</i>]isoquinolin-5- yl]phenol	HO N N N N
26	4-[8-(methyloxy)-1- (phenylmethyl)-3 <i>H</i> - pyrazolo[3,4- <i>c</i>]isoquinolin-5- yl]phenol	HO N N N N N N N N N N N N N N N N N N N
221	6,9-difluoro-5-(2-imino-3-methyl-2,3-dihydro-1,3-thiazol-5-yl)-1-methyl-3 <i>H</i> -pyrazolo[3,4- <i>c</i>]isoquinolin-8-ol	H N NH

53. (previously presented) A pharmaceutical composition comprising the compound according to claim 31 and a pharmaceutically acceptable carrier.

Attorney Docket No.: EX04-017C-US Page 46 of 47

USSN: 10/565,657

54. (withdrawn-currently amended) A method of modulating the *in vivo* activity of a kinase, the method comprising administering to a subject an effective amount of the compound or the pharmaceutical composition according to claim 31.

- 55. (withdrawn) The method according to claim 54, wherein the kinase is ALK.
- 56. (withdrawn) The method according to claim 55, wherein modulating the *in vivo* activity of ALK comprises inhibition of ALK.
- 57. (withdrawn-currently amended) A method of treating diseases or disorders associated with uncontrolled, abnormal, and/or unwanted cellular activities, the method comprising administering, to a mammal in need thereof, a therapeutically effective amount of the compound or the pharmaceutical composition as described in any one of claims claim 31.
- 58. (withdrawn) The method of claim 57 where the disease is an ALK-positive lymphomas, B-cell lymphoma, neuroblastoma, or inflammatory myofibroblastic tumors.